Dr. Charles L. Sawyers

Dr. Charles L. Sawyers is a globally recognized physician-scientist and hematologic oncologist at Memorial Sloan Kettering Cancer Center (MSK) in New York and a visionary of molecularly targeted therapies, revolutionizing the management of leukemia and prostate cancer. * **Professional Background** * Practicing physician and faculty for 35+ years, since 1993. * The first Marie-Jose and Henry R. Kravis Chair in Human Oncology and Pathogenesis and Program Chair of the Human Oncology and Pathogenesis Program (HOPP) at MSK (2006 - present). * Investigator, Howard Hughes Medical Institute (HHMI). * Specialties include chronic myeloid leukemia (CML), prostate cancer, glioblastoma, and drug resistance mechanisms. * MD, 1985, Johns Hopkins University School of Medicine; BA, Princeton University. * Internship, UCSF; Residency, UCSF; Fellowship, UCLA. * **Major Achievements** * Led the research and clinical development team of imatinib (Gleevec), which was approved to treat CML, and the team that developed dasatinib, which treats imatinib resistant CML. Dr. Sawyers and his collaborators received the 2009 Lasker-DeBakey Clinical Medical Research Award for the development of imatinib and dasatinib. * Co-discovered enzalutamide (approved to treat advanced prostate cancer, 2012) and apalutamide (approved to treat advanced prostate cancer, 2019). * Elected as a Member of the National Academy of Sciences, the National Academy of Medicine, and the American Academy of Arts and Sciences. * 2013 Breakthrough Prize in Life Sciences; former President of the American Association for Cancer Research (AACR) and American Society for Clinical Investigation (ASCI). Dr. Sawyers' extensive bench-to-bedside efforts have developed multiple FDA-approved agents to date that have radically altered outcomes for patients with leukemia and advanced prostate cancer.